# Ketones, SGLT2, HFrEF

> **NCT06229678** · EARLY_PHASE1 · RECRUITING · sponsor: **The University of Texas Health Science Center at San Antonio** · enrollment: 71 (estimated)

## Conditions studied

- Type2diabetes
- Heart Failure With Reduced Ejection Fraction

## Interventions

- **DRUG:** Empagliflozin 25 MG Oral Tablet
- **DRUG:** Placebo
- **DRUG:** Acipimox 250 Mg Oral Capsule

## Key facts

- **NCT ID:** NCT06229678
- **Lead sponsor:** The University of Texas Health Science Center at San Antonio
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-25
- **Primary completion:** 2026-11-01
- **Final completion:** 2027-03-01
- **Target enrollment:** 71 (ESTIMATED)
- **Last updated:** 2026-02-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06229678

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06229678, "Ketones, SGLT2, HFrEF". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT06229678. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*